Q1 earnings seasons to show weakness, yet markets are to be supported by a stabilizing macro momentum and dovish central banks

The Q1 reporting season should reflect current macro weakness and uncertainty linked to Brexit and trade. Q1 yearly earnings growth estimate in the US has already decreased massively during the last year: from +10.6% in April 2018, or +5.3% in January 2019, to current -2.5%. 

Highlights:

  • The Q1 reporting season should reflect current macro weakness and uncertainty linked to Brexit and trade.
  • Q1 yearly earnings growth estimate in the US has already decreased massively during the last year: from +10.6% in April 2018, or +5.3% in January 2019, to current -2.5%.
  • Indeed, the first 29 results in the US show a -2.6% yearly earnings growth compared to 17.6% in Q4. But the sales growth looks healthier at +3.7% (7.5% in Q4).
  • Earnings surprises are positive at 4% vs -0.9% in Q4 and the median sector shows an even higher +4.8% vs 3.3% in Q4. Sales surprises are positive, too, at 0.7% (-0.2 in Q4).
  • Overall we cannot expect too positive results and guidance, and estimates for 2019 and 2020 can continue to be slightly adjusted downward but the point is that results should paint a picture that investors have already acknowledged.
  • Of course, major negatives will not be, as always, taken well, also because the market is up 15% year-to-date, so we cannot exclude some risks in the short term.
  • But more relevant will be the current stabilization in the macro and monetary condition indicators and, most of all, the reaffirmed dovish stance by central banks which in turn supports investor as well as firms and households’ confidence.

Download the full publication below

Q1 EARNINGS SEASONS TO SHOW WEAKNESS, YET MARKETS ARE TO BE SUPPORTED BY A STABILIZING MACRO MOMENTUM AND DOVISH CENTRAL BANKS

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis. Currently, among European equity sectors, financials, energy, telecoms, and autos look undervalued while Pharma, utilities and software appear overvalued.
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.